Mei-Yin Polley to Remission Induction
This is a "connection" page, showing publications Mei-Yin Polley has written about Remission Induction.
Connection Strength
0.036
-
Randomized trial of ofatumumab and bendamustine versus ofatumumab, bendamustine, and bortezomib in previously untreated patients with high-risk follicular lymphoma: CALGB 50904 (Alliance). Cancer. 2019 10 01; 125(19):3378-3389.
Score: 0.036